palovarotene


( Last Updated : September 22, 2022)
Generic Name:
palovarotene
Project Status:
Pending
Therapeutic Area:
Fibrodysplasia Ossificans Progressiva
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Call for patient/clinician input open:
Brand Name:
Sohonos
Project Line:
Reimbursement Review
Project Number:
SR0761-000
Call for patient/clinician input closed:

Details


Manufacturer Requested Reimbursement Criteria1:
Sohonos (palovarotene capsules) is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with Fibrodysplasia (myositis) Ossificans Progressiva.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Sohonos (palovarotene capsules) is indicated to reduce the formation of heterotopic ossification in adults and children aged 8 years and above for females and 10 years and above for males with Fibrodysplasia (myositis) Ossificans Progressiva.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.